Job offer – Scientific and Patient Information Manager

    Job Title: Scientific and Patient Information Manager Position Type: Full-time/permanent  Location: Home-based/Remote. Must be based in the UK, Germany, France or Spain Travel required: 25 days/year (approx.) Gross salary: 40.000 – 46.000 euros (depending on experience)   Please, send your CV and cover letter at .  Applications without a cover letter will be rejected.   As Scientific and Patient Information Manager, you will work in the Medical Education and Scientific Engagement team at Myeloma…

Job offer – Research assistant

  Location: UK / home based Position : 40 hours per week / permanent Travel required: 10 days / year (approx.) Gross Salary Range: £28,000– £33,000 depending on experience Starting date: hiring immediately   We are seeking a Research Assistant to support the research activities of the Patient Evidence Department of Myeloma Patients Europe (MPE). Please, send your CV and cover letter at . Applications without a cover letter will be rejected.  The following tasks and core…

Watch the recording of webinar “AL amyloidosis treatment updates and patient experiences”

  Myeloma Patients Europe (MPE) held a webinar to summarise the most important AL amyloidosis updates and share patient experiences with therapies like CAR-T and CAEL-101.  The webinar took place on 16th April 2024 and was given by Dr. Moshe Gatt, Physician Researcher Haematologist at the Hebrew University of Jerusalem, Israel, along with two AL Amyloidosis patients from Israel, Naphtali Mastboim and Melvin Granatstein. Watch the recording below:  

European Commission approves CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

  The European Commission has approved marketing authorisation extension for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD – such as lenalidomide and pomalidomide) and a proteasome inhibitor (PI – such as bortezomib or carfilzomib), have demonstrated disease progression on the last therapy and are refractory (i.e. no longer responding) to lenalidomide. This follows an earlier…

MPE launches the Myeloma and AL Amyloidosis European Clinical Trial Navigator

  Brussels, 23 April 2024 – Myeloma Patients Europe (MPE) has launched today the English version of the Myeloma and AL Amyloidosis European Clinical Trial Navigator, an online search tool to learn about and find clinical trials for myeloma, monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple myeloma (SMM) and AL amyloidosis in Europe. With this tool, MPE wants to facilitate the search of clinical trials for these conditions and provide to patients, carers and…

Q&A: US Food and Drug Administration (FDA) approves MRD as a basis for accelerated approval in myeloma

  Last Friday, the US FDA’s Oncology Drugs Advisory Committee (ODAC) (FDA being the US medicines regulator) voted 12 – 0 to approve minimal residual disease (MRD) as an accepted endpoint for accelerated approval of new myeloma drugs. The committee’s primary role is to review benefit-risk data of new cancer drugs. You can see the full meeting and evidence considered here. The decision means that myeloma drugs may now be approved earlier in the US…

MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulation

  The European Commission recently held an online public consultation on the first draft implementing act supporting the EU health technology assessment (HTA) regulation. The EU HTA regulation will be implemented from 2025 and aims to increase the collaboration on health technology assessment across EU member states. Implementing acts set out the legislative detail of different elements of a regulation. The first of six implementing acts, the draft outlines the process for conducting joint clinical…

Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”

  Myeloma Patients Europe (MPE) will hold the webinar “AL amyloidosis treatment updates and patient experiences on new therapies” on Tuesday 16 April from 17:00 – 18:00 CEST. The webinar will be given by Dr. Moshe Gatt, Physician Researcher Haematologist at the Hebrew University of Jerusalem, Israel, along with two AL Amyloidosis patients from Israel, Naphtali Mastboim and Melvin Granatstein, who will share their experiences with new therapies like CAR-T and CAEL-101. If you would…

Snežana Doder, young myeloma patient: “When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly”

  My name is Snežana Doder and I´m from Serbia. When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly. I had a very healthy lifestyle before and underwent regular medical checkups. I am certain that this is why I discovered everything just in time, or even earlier. I was diagnosed completely by accident. I had not experienced any symptoms. Still, I found out that I…